Boston Scientific Debt to Equity Ratio 2006-2018 | BSX

Current and historical debt to equity ratio values for Boston Scientific (BSX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Boston Scientific debt/equity for the three months ending September 30, 2018 was 0.58.
Boston Scientific Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $4.81B $8.29B 0.58
2018-06-30 $4.81B $7.74B 0.62
2018-03-31 $4.80B $7.03B 0.68
2017-12-31 $3.82B $7.01B 0.54
2017-09-30 $4.42B $7.59B 0.58
2017-06-30 $4.82B $7.24B 0.67
2017-03-31 $5.51B $7.05B 0.78
2016-12-31 $5.42B $6.73B 0.81
2016-09-30 $5.17B $6.48B 0.80
2016-06-30 $5.17B $6.22B 0.83
2016-03-31 $5.42B $6.46B 0.84
2015-12-31 $5.67B $6.32B 0.90
2015-09-30 $5.80B $6.41B 0.90
2015-06-30 $5.07B $6.58B 0.77
2015-03-31 $3.85B $6.50B 0.59
2014-12-31 $3.84B $6.46B 0.60
2014-09-30 $4.25B $6.70B 0.63
2014-06-30 $4.25B $6.54B 0.65
2014-03-31 $4.25B $6.53B 0.65
2013-12-31 $4.24B $6.54B 0.65
2013-09-30 $4.25B $6.56B 0.65
2013-06-30 $3.65B $6.60B 0.55
2013-03-31 $4.25B $6.50B 0.65
2012-12-31 $4.25B $6.87B 0.62
2012-09-30 $4.25B $6.83B 0.62
2012-06-30 $4.25B $7.73B 0.55
2012-03-31 $4.26B $11.40B 0.37
2011-12-31 $4.26B $11.35B 0.38
2011-09-30 $4.26B $11.52B 0.37
2011-06-30 $4.20B $11.54B 0.36
2011-03-31 $4.67B $11.37B 0.41
2010-12-31 $4.93B $11.30B 0.44
2010-09-30 $5.13B $11.04B 0.47
2010-06-30 $5.18B $10.89B 0.48
2010-03-31 $5.67B $10.78B 0.53
2009-12-31 $5.92B $12.30B 0.48
2009-09-30 $5.77B $13.30B 0.43
2009-06-30 $5.92B $13.41B 0.44
2009-03-31 $6.24B $13.28B 0.47
2008-12-31 $6.74B $13.17B 0.51
2008-09-30 $6.77B $15.69B 0.43
2008-06-30 $7.01B $15.64B 0.45
2008-03-31 $7.31B $15.39B 0.48
2007-12-31 $7.93B $15.10B 0.53
2007-09-30 $7.90B $15.52B 0.51
2007-06-30 $8.25B $15.80B 0.52
2007-03-31 $8.90B $15.55B 0.57
2006-12-31 $8.90B $15.30B 0.58
2006-09-30 $8.89B $15.02B 0.59
2006-06-30 $8.89B $14.89B 0.60
2006-03-31 $1.84B $4.67B 0.39
2005-12-31 $1.86B $4.28B 0.44
2005-09-30 $2.43B $3.90B 0.62
2005-06-30 $1.52B $4.22B 0.36
2005-03-31 $1.12B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $48.834B $9.048B
Boston Scientific Corporation transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader they advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $123.892B 25.10
Medtronic (MDT) Ireland $122.046B 18.71
Stryker (SYK) United States $62.759B 23.66
Baxter (BAX) United States $34.600B 22.34
Zimmer Biomet Holdings (ZBH) United States $23.151B 15.01
Smith & Nephew SNATS (SNN) United Kingdom $15.845B 0.00
ResMed (RMD) United States $14.616B 27.87
Perrigo (PRGO) Ireland $8.530B 12.95
Bio-Rad Laboratories (BIO) United States $8.041B 51.42
Canopy Growth (CGC) Canada $7.608B 0.00
Hill-Rom Holdings (HRC) United States $6.079B 19.27
Aurora Cannabis (ACB) Canada $5.873B 32.05
Haemonetics (HAE) United States $5.316B 46.75
ICU Medical (ICUI) United States $4.835B 26.94
Insulet (PODD) United States $4.492B 0.00
Hutchison China MediTech (HCM) China $4.108B 0.00
Agios Pharmaceuticals (AGIO) United States $3.867B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.782B 0.00
Neogen (NEOG) United States $3.211B 48.63
NuVasive (NUVA) United States $3.153B 29.33
National Vision Holdings (EYE) United States $2.871B 55.54
Quidel (QDEL) United States $2.378B 31.00
Aphria (APHA) $2.260B 0.00
NxStage Medical (NXTM) United States $1.935B 0.00
Phibro Animal Health (PAHC) United States $1.371B 19.41
AtriCure (ATRC) United States $1.182B 0.00
Cardiovascular Systems (CSII) United States $0.999B 1439.50
VAREX IMAGING (VREX) United States $0.974B 19.57
Meridian Bioscience (VIVO) United States $0.833B 26.55
OraSure Technologies (OSUR) United States $0.761B 42.86
Surmodics (SRDX) United States $0.759B 115.98
Eagle Pharmaceuticals (EGRX) United States $0.737B 23.64
MacroGenics (MGNX) United States $0.713B 0.00
PetIQ (PETQ) United States $0.704B 20.01
Cerus (CERS) United States $0.692B 0.00
Lantheus Holdings (LNTH) United States $0.627B 19.41
Omeros (OMER) United States $0.617B 0.00
Owens & Minor (OMI) United States $0.546B 6.18
LeMaitre Vascular (LMAT) United States $0.537B 26.39
NanoString Technologies (NSTG) United States $0.509B 0.00
Insys Therapeutics (INSY) United States $0.499B 0.00
TG Therapeutics (TGTX) United States $0.428B 0.00
Evolus (EOLS) United States $0.377B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.342B 22.12
Cytosorbents (CTSO) United States $0.316B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.258B 0.00
Surface Oncology (SURF) United States $0.230B 0.00
Rockwell Medical (RMTI) United States $0.205B 0.00
Bovie Medical (BVX) United States $0.193B 0.00
BioLife Solutions (BLFS) United States $0.186B 250.75
Chimerix (CMRX) United States $0.168B 0.00
Fonar (FONR) United States $0.141B 7.07
Conatus Pharmaceuticals (CNAT) United States $0.136B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.116B 0.00
Chembio Diagnostics (CEMI) United States $0.108B 0.00
United-Guardian (UG) United States $0.080B 16.68
Female Health (VERU) United States $0.074B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.072B 0.00
InfuSystems Holdings (INFU) United States $0.068B 0.00
Trinity Biotech (TRIB) Ireland $0.059B 18.87
CAS Medical Systems (CASM) United States $0.051B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.027B 0.00
Myomo (MYO) United States $0.023B 0.00
Akers Biosciences Inc (AKER) United States $0.022B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.017B 0.00
Senestech (SNES) United States $0.016B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00